

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

CD44 Antibody, anti-human, FITC, REAfinity™

RRID:AB_2726117

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-341, RRID:AB_2726117

Antibody Information

URL: http://antibodyregistry.org/AB_2726117

Proper Citation: Miltenyi Biotec Cat# 130-113-341, RRID:AB_2726117

Target Antigen: CD44

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-292. (RRID:AB_2658163).

Antibody Name: CD44 Antibody, anti-human, FITC, REAfinity™

Description: This monoclonal targets CD44

Target Organism: human

Clone ID: clone REA690

Antibody ID: AB_2726117

Vendor: Miltenyi Biotec

Catalog Number: 130-113-341

Record Creation Time: 20231110T033655+0000

Record Last Update: 20260829T132158+0000

Ratings and Alerts

No rating or validation information has been found for CD44 Antibody, anti-human, FITC, REAfinity™.

No alerts have been found for CD44 Antibody, anti-human, FITC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Muller L, et al. (2025) EMT-driven plasticity prospectively increases cell-cell variability to promote therapeutic adaptation in breast cancer. Cancer cell international, 25(1), 32.

Bose S, et al. (2025) Inhibition of DNA polymerase eta-mediated translesion DNA synthesis with small molecule sensitises ovarian cancer stem-like cells to chemotherapy. British journal of pharmacology, 182(15), 3594.